Bayer may be next in line for anticoagulant lawsuits

Now it is Bayer’s turn. Less than a month after Boehringer Ingelheim set aside $650 million to settle lawsuits in the U.S. over its anticoagulant dabigatran (Pradaxa), rival Bayer received its first round of similar claims over rivaroxaban (Xarelto), according to the Frankfurter Allgemeine Zeitung newspaper.